human normal prostate cells pnt2  (ATCC)

Journal: Cancer Biology & Therapy

Article Title: CPT1A mediates the succinylation of SP5 which activates transcription of PDPK1 to promote the viability and glycolysis of prostate cancer cells

doi: 10.1080/15384047.2024.2329372

Figure Lengend Snippet: CPT1A is highly expressed in PCa tissues and cell lines. (a) GEPIA was used to analyze the dysregulated expression of CPT1A in PCa. PRAD: prostate adenocarcinoma. T: tumor and N: normal. (b) The expression of CPT1A in PCa tissues and the normal tissues was detected by qPCR. (c) The expression of CPT1A in PCa cell lines and the prostate epithelial cell line (PNT2) was detected by qPCR. * p <.05 in (A). ** p < .01, *** p < .001 vs PNT2 group.

Article Snippet: HEK-293T cells, normal human epithelial prostate PNT2 cells and the PCa cell lines including DU145, LNCap, 22Rv1 and VCaP were purchased from ATCC (USA) and were maintained in Dulbecco’s modified eagle medium containing 10% fetal bovine serum and 1% penicillin/streptomycin (all from Thermo Fisher Scientific, USA).

Techniques: Expressing

Journal: British Journal of Cancer

Article Title: Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer

doi: 10.1038/s41416-023-02557-8

Figure Lengend Snippet: a Illustration of fatty acid oxidation in the peroxisome and mitochondria. Thioridazine (TDZ) is an inhibitor of perFAO. b Heatmap of peroxisomal β-oxidation (perFAO) gene expression in Taylor and Grasso cohorts. We manually curated a list of perFAO genes based on Gene Ontology pathway. Cell viability of ( c ) castrate-resistant C42B, 22Rv1 and V16D, and enzalutamide-resistant MR49F prostate cancer cell lines across a range of TDZ doses. d C42B and 22Rv1 prostate cancer cell lines treated with 2.5 µM TDZ were assessed for cell migration using transwell migration assay. Scale bar: left, 100 µm; right, 200 µm. e Immunostaining for proliferative marker Ki67 in vehicle (VEH) or TDZ-treated (20 μM) patient-derived explants (PDEs). Immunohistochemical staining and quantification of the proliferative marker Ki67 is shown ( n = 11). Scale bar, 50 µm. f DECR2 expression with respect to tumour progression in four independent datasets. DECR2 levels were analysed in normal, primary, and metastatic castrate-resistant or neuroendocrine tissue samples. g The association of DECR2 expression and disease-free survival in the MSKCC (Taylor) cohort. h DECR2 protein expression in non-malignant prostate cell lines (PNT1 and PNT2) and prostate cancer cell lines (LNCaP, VCaP, C42B, 22Rv1, V16D, PC3), including enzalutamide-resistant prostate cancer cell line (MR49F). i Left : Representative DECR2 IHC staining of benign prostate tissues and prostate cancer tissues. Scale bar, 50 µm. Middle : DECR2 protein expression in a validation cohort consisting of benign prostate tissues ( n = 3) and prostate cancer tissues ( n = 10). Right : Intra-tissue IHC analysis of DECR2 expression in prostate cancer tissues ( n = 10). All cell line data are representative of at least two independent experiments and presented as mean ± s.e.m of triplicate wells. Statistical analysis was performed using ordinary one-way ANOVA or two-tailed student’s t test. Data in ( e ) were statistically analysed using paired t-test. Data in ( g ) were statistically analysed using a two-sided log-rank test. * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.

Article Snippet: Human immortalised normal prostate epithelial cell lines PNT1 and PNT2 were obtained from the European Collection of Authenticated Cell Cultures (ECACC).

Techniques: Gene Expression, Migration, Transwell Migration Assay, Immunostaining, Marker, Derivative Assay, Immunohistochemical staining, Staining, Expressing, Immunohistochemistry, Biomarker Discovery, Two Tailed Test